Histogenics Corporation Announces Pricing of Initial Public Offering
WALTHAM, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the pricing of its underwritten initial public offering of 5,909,091 shares of its common stock at a price to the public of $11.00 per share. The shares are expected to begin trading on the NASDAQ Global Market under the ticker symbol “HSGX” on December 3, 2014. Histogenics has granted the underwriters a 30-day option to purchase up to an additional 886,364 shares of its common stock to cover overallotments, if any, at the initial public offering price. The net offering proceeds to Histogenics from the sale of the shares are expected to be approximately $57.2 million, after deducting underwriting discounts and commissions and estimated offering expenses, and excluding any exercise of the underwriters’ overallotment option.
Cowen and Company, LLC, Needham & Company, LLC and Canaccord Genuity Inc. are acting as the joint book-running managers and BTIG, LLC is acting as co-manager for the offering.
The shares described above will be issued pursuant to a written prospectus forming part of the registration statement on Form S-1 filed with and declared effective by the Securities and Exchange Commission. Copies of the prospectus may be obtained by sending a request to: Cowen and Company, LLC on behalf of the underwriters, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
Elissa Cote Tel: +1 (781) 547-7900